FINWIRES · TerminalLIVE
FINWIRES

SHA:601607

3 stories mentioning SHA:601607

Every FINWIRES story that references SHA:601607, newest first.

Asia

Shanghai Pharmaceuticals Gets Nod for Manufacturing of Roxadustat Capsules

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) received a drug registration certificate from China's National Medical Products Administration for the manufacturing of Roxadustat capsules, according to a Shanghai bourse filing on Saturday.The pharmaceutical company's Hong Kong shares rose 1% during Monday's afternoon trade.The drug is used for the treatment of anemia caused by chronic kidney disease.

HKG:2607SHA:601607
Asia

Shanghai Pharmaceuticals Gains Thai Approval for Rivaroxaban Tablets

Shanghai Pharmaceuticals (SHA:601607) unit Changzhou Pharma obtained Thai Food and Drug Administration approval for rivaroxaban tablets in 10-milligram, 15-milligram and 20-milligram strengths.The generic drug is used to reduce stroke risk in non-valvular atrial fibrillation patients and treat deep vein thrombosis and pulmonary embolism, according to a Friday filing with the Shanghai bourse.

SHA:601607
Asia

Shanghai Pharmaceuticals' Profit Climbs 6.4% in Q1

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) recorded a 6.4% rise in attributable profit in the first quarter of 2026 to 1.42 billion yuan from 1.33 billion yuan a year prior, according to a Wednesday Hong Kong bourse filing.The pharma company's earnings per share rose to 0.3823 yuan from 0.3595 yuan in the corresponding period of the previous fiscal year.Revenue jumped 6.4% to 75.3 billion yuan from 70.8 billion yuan in the year-ago period.

HKG:2607SHA:601607